Study of a New Clinical Device for Reducing Body Core Temperature

Study Overview
=================
Brief Summary
-----------------
This is a descriptive, nonrandomized, noninvasive, single-group, single-center pilot study of a Core Cooling System (CCS) device for reducing core body temperature in ICU patients at University Medical Center Brackenridge (UMCB) and Seton Medical Center Austin (SMCA). The proposed research on human subjects will provide data that will be used to improve a specialized human heat transfer technique/device. By stimulating specialized blood vessels (arteriovenous anastomoses) AVAs in the palm of the hand, it is possible to greatly increase local blood flow and thus greatly increase the potential for effective heat transfer between the environment and body. The hypothesis of this trial is that the Core Cooling System (CCS) will prove to be a practical, safe, and effective method to raise or lower body temperature in critically ill patients.

Detailed Description
-----------------
Introduction: The ability to manipulate body core temperatures quickly and effectively would impact a number of fields, with truly transformative potential. By far the best way to effect a change in body temperature is perfusion with cooled or warmed blood because the vasculature of the human body equilibrates magnificently well with the body and especially the body core tissues due to the diffuse microcirculation. This process is quite invasive, however, and noninvasive techniques to date have mostly revolved around various surface heat transfer mechanisms that ultimately rely on relatively inferior conduction heat transfer. Grahn, et al., at Stanford University have identified a new technique to increase the rate of heat transfer between the skin and the body core by up to a factor of ten by harnessing the convective power of the circulatory system in a completely noninvasive way [1, 2]. Our system is derivative of the Stanford device, but different in many significant ways. A well-understood and thus modifiable system capable of rapid artificial heat transfer has almost limitless potential applications, including treatment of acute brain trauma (where the single greatest challenge to treatment is inducing immediate hypothermia), athletic performance enhancement, military operations, and enhancement of industries in which workers are subject to extreme thermal stress. Description of the Technology/Device: The technology works as a two-step process, consisting of first stimulating the blood flow to the AVAs and second cooling the glabrous skin through which blood is flowing. Accordingly, the device consists of two components: first a blood flow stimulation source, and second a surface heat exchanger to chill the glabrous skin and thereby the blood flowing through it that subsequently flows back to the body core, where it cools those tissues. Two separate means of stimulation will be tested in the trial: Transcutaneous Electrical Nerve Stimulation (TENS) - An FDA-approved TENS unit sends a current via surface electrodes through the skin to stimulate the nerves that control the state of AVA vasoconstriction. This stimulation will create a vasodilation effect in the AVAs, allowing an increase in blood flow. Mild thermal stimulation along the skin overlying the cervical spine to send a control signal to vasodilate the AVAs and provide an increased blood flow to glabrous skin. An FDA-approved electric heating pad is used for this purpose at a temperature of 42°C or lower. Cooling will be accomplished by applying water perfusion bladders to the hands and feet. The water will recirculate through the bladders to a holding tank with an internal pump, and a thermoelectric cooler regulates the water temperature. The water temperature will be at 20°C or higher. Research Incentive: The AVA structures in glabrous (non-hairy) skin are one component of the body's natural thermoregulatory system. The anatomy and morphology of AVAs have been described to a great extent in the literature, e.g. Sherman [6]. Putative pre-AVA sphincters are thought to be the primary controllers of perfusion through AVAs, regardless of the level of AVA vasodilation. If the AVAs are completely dilated, but the sphincters closed, blood will pool in the dilated AVAs, but the flow of blood, which is essential for heat exchange with the core, will be minimal. In contrast to perfusion of capillaries, which is largely regulated by local conditions, flow through AVAs appears to be mostly centrally mediated, controlled primarily by the vasoconstrictor tone imparted by rich sympathetic innervation [7-10]. The sympathetic vasoconstrictor tone, which appears to oscillate in a characteristic manner over time, is controlled by the central nervous system's homeostatic centers that respond to various centrally located core temperature receptors. The complete inner workings of this control system and its effector mechanisms are not completely understood or quantified, and other factors influence AVA blood flow to some degree, such as local skin temperatures, the presence of vasoactive metabolites, level of exercise, and stimulation of various peripheral thermal sites. Recent work in the Diller lab has indicated the potential inherent in the latter. The lab has identified regions of the skin that may be non-energetically thermally stimulated (heating over a small area so as not to warm a significant volume) to induce AVA vasodilation. We hypothesize these sites contain important thermoafferent sensors that impact the central component (hypothalamic) of the governing controller. The ability to induce mild hypothermia from a normothermic state represents the application of greatest interest to our research group. If optimally developed, a device capable of inducing only a 2-4°C decrease in body core temperature could have a huge impact in treatment of various medical disease states and/or emergencies, including cardiac arrest, severe brain injury, and stroke. It is well known that tissue death due to traumatic physical injury and/or ischemia can be decreased with therapeutic hypothermia because of the temperature dependence of cellular metabolism and the complex, destructive biochemical processes that occur in damaged tissues [12]. Therapeutic hypothermia has been shown to have a great effect in various animal models; however, translation of these results to the clinical domain has been very difficult. Aside from any possible interspecies physiological differences, researchers are able to produce injury and cool the core of the research animals in a very controlled manner, and most importantly, cooling is induced very soon after injury. From these experiments, it has been suggested that a window of opportunity exists of about 90 minutes post injury, after which little to no therapeutic effect occurs from mild hypothermia. Moreover, this 90-minute threshold may itself be a stretch, and cooling within a 60-minute window may be most appropriate. Clinically, cooling within the former and surely the latter windows has almost never been achieved. There are a number of reasons for this: the time between injury and mobilization of the patient, transportation to an emergency care facility, initial assessment of the patient in the hospital setting, and most importantly for physiological science, a lack of fast and effective methods to cool the body core. Due to simple size and geometry, the human body is much more difficult to heat or cool than, for example, the rat model. This is especially true for conductive heat transfer mechanisms (which is what most current noninvasive therapeutic hypothermia implementations are based on) because of the relatively small ratio of surface area to thermal mass volume [3]. We hope that the problem of rapid core temperature manipulation can be drastically improved upon, specifically by utilizing convective heat transfer through AVAs of glabrous skin. In these experiments, we believe an optimized combinatorial protocol utilizing large coverage of glabrous regions (both palms plus soles of the feet), manipulation of mean skin temperature, and especially optimized stimulation of peripheral thermoafferent sensors located in regions of the body such as along the spine, can allow for mild hypothermia induction in spite of the conflict with the thermoregulatory controller. We especially hope that manipulation of important thermoafferents will allow us to trick the controller and bypass its effective vasoconstrictive signal.

Official Title
-----------------
Study of a New Clinical Device for Reducing Body Core Temperature

Conditions
-----------------
Hypothermia

Intervention / Treatment
-----------------
* Device: CCS Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Admitted to UMCB ICU Sedated, intubated and or mechanically ventilated At least one core temperature measurement device in place (rectal, bladder, pulmonary artery) as standard of care Medical/surgical condition is stable enough to permit uninterrupted testing and observation for at least 24 hours No medical/surgical procedures are anticipated as necessary or scheduled during testing and observation period that would be affected by this protocol Vital signs and other parameters have been stable for at least 12 hours and there are no imminent indications of instability LAR available and willing to provide informed consent Exclusion Criteria: Condition is too unstable to permit uninterrupted testing and observation Pregnant and breast feeding patients Patients that might worsen with TH, including coagulopathy (INR>1.5), thrombocytopenia (platelet count <100,000) Patients on antiplatelet therapy other than aspirin Patients on anticoagulants other than prophylactic low molecular weight heparin Patients on pressors to maintain blood pressure Patients with injuries to extremities that could preclude application of cooling mittens or socks to at least three extremities Patients on TH treatment for any other condition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Device<br>CCS Device application | Device: CCS Device<br>* Core Cooling System Device<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events From Application and Use of the Core Cooling System (CCS) Device. | Assess and capture all adverse events (if any) from application and use of the CCS device. Also assess CCS device interference with participant's standard of care. | 1 year after the enrollment is closed | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participant's With Adverse Events From Induction of Therapeutic Hypothermia (TH). | Assess and capture all adverse events from induction of TH with CCS device. | 1 year after the enrollment is closed. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Induced therapeutic hypothermia